---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-012664"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2026-01-14T23:59:59+00:00"
generated_at: "2026-05-16T10:25:51.206998+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sana: UP421 survives 12 months in T1D with no immunosuppression; plans SC451 IND, SG293 data in 2026

## Summary
- UP421, a hypoimmune pancreatic islet cell therapy, continued to survive and function at 12 months post-transplant in a T1D patient with no immunosuppression.
- On track to file an IND and begin Phase 1 trial for SC451, an iPSC-derived islet cell therapy, as early as 2026.
- Goal to generate initial human data in 2026 for SG293, an in vivo CD19-directed CAR T cell therapy.

## SEC filing metadata
- accession: 0001193125-26-012664
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2026-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000119312526012664/0001193125-26-012664-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000119312526012664/sana-20260114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-012664
- JSON: https://secwatch.observer/filing/0001193125-26-012664.json
- Plain text: https://secwatch.observer/filing/0001193125-26-012664.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.